Meeting Banner
Abstract #2921

MRI biomarkers for PEGPH20-enhanced treatment of pancreatic ductal adenocarcinoma

Ezekiel Maloney1, Christopher DuFort2, Ravneet Vohra1, Markus Carlson2, Navid Farr3, Paolo Provenzano4, Joshua Park1, Sunil Hingorani2, and Donghoon Lee1

1Radiology, University of Washington, Seattle, WA, United States, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 3Medical Devices Research, National Inststitute of Health, Bethesda, MD, 4Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN

Pancreatic cancer is a devastating disease with poor prognosis. Pancreatic tumor therapy has been ineffective in part because pancreatic tumors have high interstitial fluid pressure (IFP), driven by high hyaluronan concentration, that inhibits penetration of drugs into the tumor. We performed multi-parametric MRI at high resolution to non-invasively assess tumor response in a KPC mouse model to pegylated recombinant hyaluronidase in isolation as well as combined with Gemcitabine. T1 and T2 relaxation as well as diffusion, and 3 dimensional volume measurements were used to characterize the tumors. MR measurements were compared with invasive IFP measurements and histopathological results.

This abstract and the presentation materials are available to members only; a login is required.

Join Here